CN103215336A - Preparation method of betulinic acid 28-O-beta-D-glucopyranoside and use of betulinic acid 28-O-beta-D-glucopyranoside - Google Patents
Preparation method of betulinic acid 28-O-beta-D-glucopyranoside and use of betulinic acid 28-O-beta-D-glucopyranoside Download PDFInfo
- Publication number
- CN103215336A CN103215336A CN2013101656831A CN201310165683A CN103215336A CN 103215336 A CN103215336 A CN 103215336A CN 2013101656831 A CN2013101656831 A CN 2013101656831A CN 201310165683 A CN201310165683 A CN 201310165683A CN 103215336 A CN103215336 A CN 103215336A
- Authority
- CN
- China
- Prior art keywords
- betulinic acid
- preparation
- glucopyranoside
- gram
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the field of biological medicines and in particular relates to betulinic acid 28-O-beta-D-glucopyranoside (I). The invention discloses a preparation method of the betulinic acid 28-O-beta-D-glucopyranoside. The preparation method comprises the following step of carrying out biotransformation onto the betulinic by a bacterial strain with a preservation number of NRRL1086. The invention further discloses a use of the betulinic acid 28-O-beta-D-glucopyranoside in anti-inflammation.
Description
Technical field
The present invention relates to the bio-pharmaceutical field, be specifically related to the preparation method of Betulinic acid 28-O-β-D-glucopyranoside, the invention also discloses the purposes of its anti-inflammatory aspect.
Background technology
Inflammation is modal a kind of pathologic process in the human diseases, with most of disease-relateds.Anti-inflammatory drug is the second largest class medicine that is only second to anti-infectives clinically, at present using more anti-inflammatory drug clinically mainly is non-steroidal anti-inflammatory medicine and adrenal cortex hormones drug, but these drug effects are many target spots, multipath, the dosage that uses and also have nothing in common with each other the course of treatment and various mechanism between also have complicated cyberrelationship, life-time service can bring a lot of untoward reactions.Along with constantly developing and be familiar with and for many years clinical and experiment confirm to Chinese medicine, a lot of Chinese medicines have good anti-inflammatory action, little and the aboundresources of toxic side effect, so the exploitation of traditional Chinese medicine monomer and structure of modification and the focus that the research of its pharmacological mechanism become new drug development in the world today.Pentacyclic triterpenoid is distributed widely in each kind of plant, has wide biological activity, studies show that to have significant activity aspect anti-inflammatory.Have tangible anti-inflammatory action as Betulinic acid, but poorly water-soluble has influenced the performance of its drug effect.Water-soluble in order to increase, keep its activity simultaneously, it has been carried out structural modification, chemosynthesis a large amount of derivatives, wherein being no lack of has active good compound to find.But the microorganism of relevant Betulinic acid is glycosylation modified rarely in report.
Microbial transformation is to utilize the specific enzymes of microorganisms exogenous compounds to be carried out the specific biochemical reaction of structural modification.Microbial transformation has the three-dimensional arrangement selectivity of height, can single-minded ground catalysis specific reaction, need not loaded down with trivial details protection and operates with deprotection, have efficiently, the advantage of environmental protection, and be a kind of effective ways that the natural radioactivity compound carries out structural modification.If in containing the lupinane type pentacyclic triterpene aglycon of carboxyl, introduce the problem that glycosyl can solve the bioavailability difference to a certain extent, keep its activity simultaneously.
Summary of the invention
The invention discloses compound in structural formula I:
Called after Betulinic acid 28-O-β-D-glucopyranoside.The present invention also comprises the solvate of compound in structural formula I simultaneously.
Table 1 Betulinic acid and Betulinic acid 28-O-β-D-glucopyranoside
13The C-NMR data are as follows:
Pharmacological testing proves that formula I compound of the present invention has excellent anti-inflammatory activity.
Formula I compound of the present invention is that substrate transforms preparation with the Betulinic acid with bioconversion method preferably, and method is as follows:
In order to seek the suitable bacterial classification that Betulinic acid becomes Betulinic acid 28-O-β-D-glucopyranoside that transforms, the present invention has screened a plurality of bacterial classifications altogether, found that, preserving number is that the NRRL1086 bacterial classification has stronger conversion capability (seeing Table 2) to Betulinic acid.
Screen used liquid nutrient medium (PDA): the fresh peeling potato of 200 grams adds boiling water 500mL and boils the 15min after-filtration, and filtrate adds glucose 20g, KH
2PO
43.0g, MgSO
40.75g, Vb
110.0mg adding distil water is settled to 1.0L, adds NaOH or HCl adjust pH to 6.0, every bottle of packing 30mL of 150mL Erlenmeyer flask liquid nutrient medium, 121 ℃, the 0.15MPa 20min that sterilizes.
During strain screening, preserve the used slant medium of bacterial classification and be and add 1.5% agar at the aforesaid liquid substratum, make behind the every pipe 5mL of 15mL tool plug test tube, 121 ℃, 0.15MPa sterilization 20min cooling.
The preservation of bacterial classification and activation: actication of culture adopts two step activation methods, referring to: Nair, M.S.R., and Basile, D.V.Bioconversion ofartenium B to artmisinn. natural product magazine (Jounal ofNatural Products) 1993,56 (9): 1559.Elder generation in liquid nutrient medium, behind 28 ℃ of 180r/min rotating and culturing 24-48h, transfers bacterial classification inoculation in another liquid nutrient medium, and inoculum size 1-5% (V/V) is with application of sample behind the condition cultivation 24h.
The preparation of sample and application of sample: Betulinic acid is dissolved in ethanol, is made into the 10mg/mL solution for standby; Every bottle through two the step activatory bacterium liquid (30mL) add the 0.5mL sample solution, make every bottle of bacterium liquid contain Betulinic acid 5mg.Behind condition cultivation 120h, stopped reaction is filtered thalline, the ethyl acetate extraction of fermented liquid usefulness equivalent 3～5 times, combining extraction liquid, recovery ethyl acetate; Obtain extracting medicinal extract, thalline extraction using alcohol 3 times, united extraction liquid reclaims ethanol, obtains extracting medicinal extract, and two kinds of medicinal extract are merged, and adds a little acetic acid ethyl dissolution reserve thin layer and identifies usefulness.
Blank: blank is established positive control (substrate+substratum), negative control (substratum+bacterium), solvent control (substratum+bacterium+ethanol), and cultivation and extraction conditions are the same.
The thin layer of converted product is identified:
The thin layer condition:
Thin layer plate: the silica gel G plate that 0.7% CMC-Na makes.
Developping agent: toluene-ethyl acetate-Glacial acetic acid (14: 4: 0.5).
Developer: 10% sulfuric acid ethanol
Operation:
Transform extract and blank extract and put respectively in thin layer plate, ascending method is fully launched back taking-up nature and is dried, and spray is with 10% sulfuric acid ethanol, 105 ℃ of heating colour developings.Conversion results sees Table 2.
Table 2 microbial transformation Betulinic acid The selection result
From The selection result, there are 2 kinds of bacterium to transform, NRRL1086, through measuring and calculating, transformation efficiency can reach 45%.And NRRL5646 is not the glycosylation conversion.Therefore, the present invention selects bacterial strain NRRL1086 for use, is that raw material prepares Betulinic acid 28-O-β-D-glucopyranoside with the Betulinic acid.
The invention discloses a kind of preparation method of preparation I compound, is that the NRRL1086 bacterial strain carries out the bio-transformation acquisition to Betulinic acid with preserving number.
Preferred method is: with the Betulinic acid is substrate, utilizes the bacterial strain of preserving number for NRRL1086, and substrate and this bacterial strain were cultivated in substratum 3～8 days altogether, and termination reaction is used organic solvent extraction, and concentrated extract separates promptly by silica gel column chromatography.
Wherein organic solvent is selected from one or more in ethyl acetate, chloroform, methylene dichloride, ethyl formate, butylacetate, toluene, normal hexane, the propyl carbinol.More preferably ethyl acetate.
The silica gel column chromatography separation is carried out gradient elution with chloroform and methyl alcohol.
Substratum contains 10～30% potato decoction liquor, KH
2PO
4, MgSO
4, VITMAIN B1 and be selected from one or more carbon sources in glucose, sucrose, bud sugar, the starch, medium pH=5.0～7.0.Be weight percentage.
Wherein by 100 milliliters of 20% potato decoction liquor, the preferred content of each component is KH in the substratum
2PO
4Contain 0.1～0.5 gram; MgSO
4Contain 0.05～0.5 gram; Glucose or sucrose 0.5-2.5 gram.
Highly preferred preparation method is: the bacterial strain that with preserving number is NRRL1086 is inoculated in the liquid nutrient medium by the inclined-plane, put 28 ℃, rotating speed is to cultivate in the shaking table of 180r/m to become seed liquor in 24 hours, and seed liquor continues to cultivate 24 hours after being forwarded to fermented liquid, adds conversion of substrate; Continue to cultivate after 144 hours and stop catalyzed reaction, filter thalline, fermented liquid is with the ethyl acetate extraction of equivalent 5 times, combining extraction liquid, reclaims ethyl acetate, obtains extracting medicinal extract, and medicinal extract is column chromatography for separation behind silica gel mixed sample; With the chloroform-methanol is elution system.Converted product obtains the white powder converted product through recrystallizing methanol.
Pharmacological testing proves that structural formula I compound of the present invention has significant anti-inflammatory activity, below is test method and result:
Betulinic acid 28-O-β-D-glucopyranoside anti-inflammatory activity research
1, the influence of Betulinic acid 28-O-β-D-glucopyranoside p-Xylol induced mice ear swelling model
Get 60 of normal mouses, male and female half and half are divided into 6 groups at random, are respectively control group, Betulinic acid group (100mg/kg), medication (25,50,100mg/kg) group, positive drug group (Naproxen Base 45mg/kg).Each organizes continuous gastric infusion three days, and once a day, control group then gives the CMC-Na of respective volume.The last administration was only evenly smeared dimethylbenzene 20 μ L/ in the positive and negative two sides of left auricle after 40 minutes, 20 minutes post-tensioning necks are put to death, and cut ears along the auricle baseline, swell with the YLS-Q4 ear and make the ear device and sweep away auricle at the same position of left and right sides ear, weigh respectively, represent the swelling degree with the difference of self left and right sides auricle quality.
Inhibiting rate=[(control group swelling degree mean value one administration group swelling mean value)/control group swelling mean value] * 100%
The result is as follows:
This shows that Betulinic acid 28-O-β-D-glucopyranoside can significantly suppress dimethylbenzene induced mice auricle acute inflammation, and its high dose group effect is better than the positive drug group and with the Betulinic acid high dose group of concentration.
2, Betulinic acid 28-O-β-D-glucopyranoside on Carrageenan causes the influence of rat paw edema model
Get 60 of normal male rats, be divided into 6 groups at random, be respectively control group, Betulinic acid group (100mg/kg), medication (25,50,100mg/kg) group, positive drug group (Naproxen Base 30mg/kg).Each organizes continuous gastric infusion three days, and once a day, control group then gives the CMC-Na of respective volume.Measure right back sufficient volume with YLS-7B toes volume determination instrument before the last administration, as administration front volume V
0, administration is after 40 minutes, and injection 1% λ-carrageenin 0.1mL/ only causes inflammation between the right back whole sole of the foot stndon sheath of rat, and 1h, 3h, 5h, 7h measure right back sufficient volume V after causing inflammation respectively
S, so that scorching forebody-afterbody product moment (V
S-V
0) be the swelling degree.
The result is as follows:
Compare with control group
*P＜0.05,
*P＜0.01
This shows, on Carrageenan causes rat paw edema after Betulinic acid 28-O-β-D-glucopyranoside medication restraining effect, and have certain concentration dependent, and its high dose group effect is better than the positive drug group and with the Betulinic acid high dose group of concentration.
3, Betulinic acid 28-O-β-D-glucopyranoside is to the influence of rat AA model
Rat grouping, medication are the same, with same lot number 80 ℃ of water-bath 1h of bacille Calmette-Guerin vaccine deactivation, be made into the emulsion of 10g/L with sterilising liq paraffin, fully grinding mixing is Cheng Foshi Freund's complete adjuvant (FCA).It is standby to place 4 ℃ of refrigerators preservations, shakes up before the use.Cause the left and right back of the scorching preceding rat following volume of articulatio talocruralis (mL) with toes volumetric measurement instrument mensuration, cause inflammation in the left back toes intradermal injection of every mouse 0.1mL FCA then, normal control group injection 0.1mLPBS.Cause scorching preceding 3 days gastric infusions.Respectively at cause scorching before and cause scorching back 6,12,18 and 24h, detect with toes volumetric measurement instrument and cause scorching forward and backward rat and cause scorching parapodum swelling, with observation AA rat primary pathology.
The result is as follows:
Compare with control group
*P＜0.05,
*P＜0.01
Each is organized rats with left foot 6h after causing inflammation and begins swelling, and 18h peaks.After Betulinic acid 28-O-β-D-glucopyranoside medication FCA inductive AA rat primary inflammation there is significant inhibitory effect, have certain concentration dependent, and its high dose group effect is better than the positive drug group and with the Betulinic acid high dose group of concentration.
Betulinic acid 28-O-β of the present invention-D-glucopyranoside can mix with pharmaceutically acceptable carrier, is used to prepare the medicine for treatment compositions.Can be prepared into formulation general on the pharmaceutics, as parenteral dosage forms such as gastrointestinal administration formulations such as capsule, tablet, pill, oral liquid, granule, tincture, sustained release dosage and injection, transdermal patch, external preparations.
Embodiment
Embodiment 1
The preparation of Betulinic acid 28-O-β-D-glucopyranoside:
Substrate Betulinic acid 200mg is dissolved in 20mL ethanol; The glucose solution 100mL of preparation 0.5g/mL, sterilization (the same PDA of condition); Bacterial classification NRRL1086 is seeded to liquid PDA substratum by 4 ℃ solid inclined-plane, and (substratum is by containing KH in 100 milliliter of 20% potato decoction liquor
2PO
40.3 gram; MgSO
40.75 gram; Glucose 10 grams; VitaminB10 .01 restrains preparation, and the liquid nutrient medium branch is filled to the triangular flask of 150mL, every bottled liquid 30mL), to shaking table, cultivate 24 hours (28 ℃ 180r/m), are seed liquor; Seed liquor is transferred under aseptic condition in the liquid PDA substratum (substratum is formed the same), in shaking table, continues to cultivate 24 hours.Every bottle adds 1mL Betulinic acid ethanolic soln and 3mL sucrose solution, cultivates termination reaction after 144 hours.The ethyl acetate extraction of fermented liquid usefulness equivalent 6 times, combining extraction liquid, recovery ethyl acetate; Obtain extracting medicinal extract 317mg, take by weighing 100-200 order silica gel 0.8g and residue and evenly mix sample, column chromatography 200～300 order 20g dry column-packings, the chloroform-methanol gradient elution, in the eluting fraction of chloroform-methanol=95: 5, can get target converted product Betulinic acid 28-O-β-D-glucopyranoside,, obtain white powder 122mg through recrystallizing methanol.
Its carbon spectrum sees Table 1
Embodiment 2
Tablet
Get Betulinic acid 28-O-β-D-glucopyranoside 100g and starch 50g that embodiment 1 makes, dextrin 50g mixes, and makes wetting agent with an amount of 30% ethanol, makes softwood, and ordinary method is granulated, and adds an amount of Magnesium Stearate and mixes, and makes tablet.
Claims (8)
1. the preparation method of compound Betulinic acid 28-O-β-D-glucopyranoside (I) or its pharmaceutically acceptable solvate,, it is characterized in that: with preserving number is that the NRRL1086 bacterial strain carries out bio-transformation to Betulinic acid and obtains.
2. the preparation method of claim 1, wherein bioconversion method is as follows: be substrate with the Betulinic acid, utilize the bacterial strain of preserving number for NRRL1086, substrate and this bacterial strain were cultivated in substratum 4～7 days altogether, termination reaction, fermented liquid organic solvent extraction, concentrated extract, get medicinal extract, separate obtaining target compound by silica gel column chromatography.
3. the preparation method of claim 2, wherein organic solvent comprises: ethyl acetate, chloroform, methylene dichloride, ethyl formate, butylacetate, toluene, hexane, propyl carbinol etc.
4. the preparation method of claim 2, substratum contains 10～30% potato decoction liquor, KH
2PO
4, MgSO
4, VITMAIN B1 and be selected from glucose, sucrose, bud sugar, the starch one or more carbon source, medium pH=5.0～7.0.
5. the preparation method of claim 2 is wherein by 100 milliliters of 20% potato decoction liquor, KH
2PO
40.1～0.5 gram; MgSO
40.05～0.5 gram; Glucose 0.5-2.5 gram (or sucrose 0.5-2.5 gram).
6. the preparation method of claim 2, wherein bacterial classification activates earlier before cultivation, soak time 20～30h.
7. pharmaceutical composition wherein contains compound or its pharmaceutically acceptable solvate and the pharmaceutically acceptable carrier of claim 1.
8. the compound of claim 1 or its pharmaceutically acceptable solvate are used to prepare the purposes of anti-inflammatory drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101656831A CN103215336A (en) | 2013-05-08 | 2013-05-08 | Preparation method of betulinic acid 28-O-beta-D-glucopyranoside and use of betulinic acid 28-O-beta-D-glucopyranoside |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101656831A CN103215336A (en) | 2013-05-08 | 2013-05-08 | Preparation method of betulinic acid 28-O-beta-D-glucopyranoside and use of betulinic acid 28-O-beta-D-glucopyranoside |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103215336A true CN103215336A (en) | 2013-07-24 |
Family
ID=48813486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013101656831A Pending CN103215336A (en) | 2013-05-08 | 2013-05-08 | Preparation method of betulinic acid 28-O-beta-D-glucopyranoside and use of betulinic acid 28-O-beta-D-glucopyranoside |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103215336A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104548120A (en) * | 2013-10-22 | 2015-04-29 | 北京林业大学 | Polyethylene glycol-betulinic acid conjugate and preparation method thereof |
| CN111825739A (en) * | 2018-06-25 | 2020-10-27 | 广东药科大学 | Anti-inflammatory triterpenoid saponin compound and extraction method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1682740A (en) * | 2005-03-11 | 2005-10-19 | 中国药科大学 | Use of pentacylic triterpene compounds in preparing glycogenic phosphorylase inhibitor |
| CN101412743A (en) * | 2008-11-27 | 2009-04-22 | 中国药科大学 | 2 alpha-hydroxy-substituted white birch keto acid, preparation thereof and anti-tumor use |
| WO2010028487A1 (en) * | 2008-09-10 | 2010-03-18 | Université Du Québec À Chicoutimi | Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents |
| CN101693913A (en) * | 2009-10-22 | 2010-04-14 | 南京启维医药科技有限公司 | Process for preparing rusco monoglycosides high-efficiently |
| CN102002081A (en) * | 2010-10-26 | 2011-04-06 | 中国药科大学 | 9-O-beta-D-glucosyl nandinine as well as preparation method and application thereof |
-
2013
- 2013-05-08 CN CN2013101656831A patent/CN103215336A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1682740A (en) * | 2005-03-11 | 2005-10-19 | 中国药科大学 | Use of pentacylic triterpene compounds in preparing glycogenic phosphorylase inhibitor |
| WO2010028487A1 (en) * | 2008-09-10 | 2010-03-18 | Université Du Québec À Chicoutimi | Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents |
| CN101412743A (en) * | 2008-11-27 | 2009-04-22 | 中国药科大学 | 2 alpha-hydroxy-substituted white birch keto acid, preparation thereof and anti-tumor use |
| CN101693913A (en) * | 2009-10-22 | 2010-04-14 | 南京启维医药科技有限公司 | Process for preparing rusco monoglycosides high-efficiently |
| CN102002081A (en) * | 2010-10-26 | 2011-04-06 | 中国药科大学 | 9-O-beta-D-glucosyl nandinine as well as preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| NAI-DONG CHEN等: ""Microbial conversion of ruscogenin by Gliocladium deliquescens NRRL1086: glycosylation at C-1"", 《APPL MICROBIOL BIOTECHNOL》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104548120A (en) * | 2013-10-22 | 2015-04-29 | 北京林业大学 | Polyethylene glycol-betulinic acid conjugate and preparation method thereof |
| CN111825739A (en) * | 2018-06-25 | 2020-10-27 | 广东药科大学 | Anti-inflammatory triterpenoid saponin compound and extraction method and application thereof |
| CN111825739B (en) * | 2018-06-25 | 2022-06-10 | 广东药科大学 | Anti-inflammatory triterpenoid saponin compound and extraction method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109534984B (en) | Method for preparing p-coumaric acid by using spartina alterniflora | |
| CN110452247B (en) | Heteroterpene compound and preparation method and application thereof | |
| CN107827805B (en) | Indole diterpenoid compound derived from mangrove plant xylocarpus meliloti fungi as well as preparation method and application thereof | |
| CN101412743B (en) | Preparation of 2 alpha-hydroxy-substituted white birch keto acid | |
| CN102675199B (en) | Protein complex acid phosphatase inhibitor as well as preparation method and purpose of protein complex acid phosphatase inhibitor | |
| CN102559828A (en) | Method for preparing astragaloside IV by converting total saponins of astragalus by microorganisms | |
| CN106336438A (en) | Succinyl ononin and applications of succinyl ononin in preparation of cardiovascular disease medicine | |
| CN103215336A (en) | Preparation method of betulinic acid 28-O-beta-D-glucopyranoside and use of betulinic acid 28-O-beta-D-glucopyranoside | |
| CN103360456B (en) | Triterpene compound and Synthesis and applications | |
| CN103739656A (en) | 28-O-beta-D-glucosyl phytolaccagenin, and preparation method and application thereof | |
| CN102002081B (en) | 9-O-beta-D-glucosyl nandinine as well as preparation method and application thereof | |
| CN103739655A (en) | 28-O-beta-D-glucosyl senegenin, and preparation method and application thereof | |
| CN103233055A (en) | Preparation method and application of oleanolic 28-O-beta-D-glucopyranoside | |
| CN103360452B (en) | The Synthesis and applications of Muskmelon Base tetracyclic triterpene cucurbitane compound | |
| CN104892713A (en) | Preparation method and applications of cucurbitacin C and analogs thereof | |
| CN103739654A (en) | 28-O-beta-D-glucosyl ursolic acid, and preparation method and application thereof | |
| CN107141335B (en) | Cyclopeptide compound and preparation method and application thereof | |
| CN102408464A (en) | Novel notriterpenoid saponin compound and preparation method and application thereof | |
| CN102342935B (en) | Berberine-phenylacetic acid derivative, pharmaceutically acceptable salt thereof and application thereof | |
| CN101693913A (en) | Process for preparing rusco monoglycosides high-efficiently | |
| CN103880678B (en) | Benzoic acid derivative and preparation thereof and hypoglycemic application | |
| CN103396462A (en) | Curcumin glucoside and preparation method and application thereof in treating Parkinson disease | |
| CN107224432B (en) | Application of compound Stemphol in preparation of antitumor drugs | |
| CN105294813A (en) | Compound holarrhine and application thereof in preparation of antibacterial medicines | |
| CN102267884B (en) | Compound and application thereof in preparation of antitumor medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130724 |
|
| WD01 | Invention patent application deemed withdrawn after publication |